<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394065</url>
  </required_header>
  <id_info>
    <org_study_id>2020-5-13 high-sensitivity PET</org_study_id>
    <nct_id>NCT04394065</nct_id>
  </id_info>
  <brief_title>uEXPLORER Total-body PET/CT in Nasopharyngeal Carcinoma</brief_title>
  <official_title>Potential of uEXPLORER Total-body PET/CT in Nasopharyngeal Carcinoma: The Dynamic Imaging, Kinetic Parameters, and Comparison With Conventional PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      uEXPLORER total-body PET/CT in Nasopharyngeal Carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner&#xD;
      (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer&#xD;
      imaging in clinical research and healthcare. The objective of this study is to determine its&#xD;
      specific effect in newly diagnosed nasopharyngeal carcinoma compared with conventional PET/CT&#xD;
      and the quantitative kinetic parameters including glucose metabolic rate (Ki), glucose&#xD;
      transport rate of flow-in (k1) and flow-out (k2) between tissue and blood, and&#xD;
      glucosamine-6-phosphatization rate in tissue (k3). All the neck lymph nodes suspected for&#xD;
      metastatic in PET/CT were biopsied under the guidance of ultrasound for a pathological&#xD;
      diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2020</start_date>
  <completion_date type="Actual">June 20, 2021</completion_date>
  <primary_completion_date type="Actual">February 20, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>The results of uEXPLORER Total-body PET/CT</measure>
    <time_frame>6 months</time_frame>
    <description>The Dynamic Imaging, Kinetic Parameters of uEXPLORER Total-body PET/CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of uEXPLORER Total-body PET/CT and Conventional PET/CT</measure>
    <time_frame>6 months</time_frame>
    <description>Image quality and Static Lesion detectability of TB-PET/CT and conventional PET/CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol of TB-PET/CT in NPC</measure>
    <time_frame>6 months</time_frame>
    <description>Acquisition time and low dose simulation of TB-PET/CT</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>uEXPLORER total-body PET/CT</arm_group_label>
    <description>Newly diagnosed NPC patients will undergo a one-hour total-body dynamic PET/CT examination and subsequently followed by a conventional PET/CT scan within 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ultrasensitive positron emission tomography</intervention_name>
    <description>A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER)</description>
    <arm_group_label>uEXPLORER total-body PET/CT</arm_group_label>
    <other_name>conventional PET/CT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        newly diagnosed NPC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be informed of the investigational nature of this study and given&#xD;
             written informed consent.&#xD;
&#xD;
          -  Aged between 18-65, male/female.&#xD;
&#xD;
          -  Histologically confirmed non-keratinizing nasopharyngeal carcinoma (including&#xD;
             differentiated type and undifferentiated type, WHO II and III)..&#xD;
&#xD;
          -  Fertile women should practice contraception during the study period.&#xD;
&#xD;
          -  HGB ≥90g/L ,WBC ≥4*109/L , PLT ≥100*109/L,&#xD;
&#xD;
          -  With normal liver function test (ALT and AST ≤2.5*ULN, TBil ≤2.0*ULN)&#xD;
&#xD;
          -  With normal renal function test (serum creatinine ≤1.5*ULN)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women in pregnancy or lactation&#xD;
&#xD;
          -  Patients with diabetes&#xD;
&#xD;
          -  Prior malignancy except adequately treated basal cell, squamous cell skin cancer, or&#xD;
             cervical cancer in situ.&#xD;
&#xD;
          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the&#xD;
             compliance of the trial, for example, unstable cardiac disease requiring treatment,&#xD;
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose&#xD;
             &gt;1.5×ULN), and emotional disturbance.&#xD;
&#xD;
          -  Already involved in other clinical trial.&#xD;
&#xD;
          -  Mental disorder, civil disability, limited capacity for civil conduct.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Haiqiang Mai, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2265-2267. doi: 10.1073/pnas.1917379117. Epub 2020 Jan 21.</citation>
    <PMID>31964808</PMID>
  </reference>
  <results_reference>
    <citation>Lv Y, Lv X, Liu W, Judenhofer MS, Zwingenberger A, Wisner E, Berg E, McKenney S, Leung E, Spencer BA, Cherry SR, Badawi RD. Mini EXPLORER II: a prototype high-sensitivity PET/CT scanner for companion animal whole body and human brain scanning. Phys Med Biol. 2019 Mar 21;64(7):075004. doi: 10.1088/1361-6560/aafc6c.</citation>
    <PMID>30620929</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hai-Qiang Mai,MD,PhD</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>ultrasensitive PET CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

